TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent;~* Patients over the age of 18;~* Recently confirmed mucinous cystic pancreatic neoplasm; may be confirmed by presence of mucin, cyst fluid carcinoembryonic antigen (CEA) above 192 U/L, or other reliable diagnostic means such as endomicroscopy; KRAS analysis may also be performed at the discretion of the Investigator;~* Unilocular cyst with diameter of at least 1.5 cm but no more than 4 cm;~* Normal hematologic, hepatic, and renal function at study entry;~* Appropriate steps taken to minimize or avoid the potential for pregnancy for subjects of child-bearing potential.\*~  * Note: A female patient is considered to be of childbearing potential unless she has had a hysterectomy, is at least one year postmenopausal or has undergone tubal ligation. For the purposes of this study, adequate birth control includes at least one medically approved and highly effective method of birth control, defined as those which result in a low failure rate (i.e., \< 1% per year) when used consistently and correctly, such as implants, injectables and oral contraceptives combined with the use of condoms. Only male patients whose vasectomy has been confirmed by semen analysis at least 3 months after the vasectomy are allowed not to use acceptable contraceptive methods.~Exclusion Criteria:~* Positive cytology indicating malignancy;~* Thrombotic or embolic events;~* Known hypersensitivity to study agent;~* Known drug or alcohol abuse;~* Pregnant or breastfeeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Escalation: NanoPac® 6 mg/mL (Type: EXPERIMENTAL): Single intracystic injection of NanoPac® at a dose of 6 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
- Dose Escalation: NanoPac® 10 mg/mL (Type: EXPERIMENTAL): Single intracystic injection of NanoPac® at a dose of 10 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
- Dose Escalation: NanoPac® 15 mg/mL (Type: EXPERIMENTAL): Single intracystic injection of NanoPac® at a dose of 15 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
- Second Phase: NanoPac® at Best Dose (Type: EXPERIMENTAL): Intracystic injection of NanoPac®. The dose administered in the second phase will be determined during the dose escalation phase. Subjects will receive two NanoPac® injections, with the second injection administered 12 weeks after the first injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of probable early Alzheimer's disease~* stable dose of acetylcholinesterase inhibitor~* community dwelling~* stable medical condition~Exclusion Criteria:~* unstable and significant medical conditions~* recurrent major psychiatric disorder~* treatment with memantine

- Gender: ALL
- Minimum Age: 56 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Azithromycin - Ivermectin Mass Drug Administration for Skin Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All community members are able to be included in the study.~Exclusion Criteria:~* Allergy to any of the components of the allocated drug regimen

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Parallel Treatment (Type: OTHER): Site 1- Parallel Treatment Arm Single dose azithromycin (for yaws) and Ivermectin/Permethrin (for scabies) will be offered on D1. A second dose of Ivermectin/Permethrin will be offered 7-14 days later.
- Sequential Treatment (Type: OTHER): Site 2- Serial Treatment Arm Ivermectin/Permethrin (for scabies) will be offered on D1 with a second dose of Ivermectin/Permethrin offered 7-14 days later..~Single dose azithromycin (for yaws) will be offered at the twelve month follow-up visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* You must be at least 18 years old.~* You must be diagnosed with major depressive disorder~* You must be able to visit the doctor's office once a week to once every 2 weeks for a total of 8 weeks.~Exclusion Criteria:~* You are a woman and are pregnant or breastfeeding.~* You have a current or previous major psychiatric disorder other than depression, such as bipolar disorder, schizophrenia, or other psychotic disorder.~* You have a history of alcohol or drug dependence or abuse within the past 6 months.~* You are allergic to the study drug or you have experienced allergic reactions when taking several medications at once.~* You have a serious medical illness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with histologically proven breast cancer, eligible for neoadjuvant or adjuvant myelosuppressive chemotherapy~2. Women ≥ 18 years of age~3. Estimated life expectancy of more than six months~Exclusion Criteria:~1. Previous or concurrent malignancy except non-invasive non-melanoma skin cancer, in situ carcinoma of the cervix, or other solid tumor treated curatively, and without evidence of recurrence for at least ten years prior to study entry~2. Any serious illness or medical condition that may interfere with safety, compliance, response to the products under investigation and their evaluation, e.g.:~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EP2006 (Type: EXPERIMENTAL): Eligible patients will be teated with EP2006
- Filgrastim (Type: ACTIVE_COMPARATOR): Eligible patients will be teated with Filgrastim

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male 40 years of age~* Clinical signs and symptoms of frequency and urgency, with or without UUI, with or without BOO, for at least three months~* Mean urinary frequency of 8 micturitions/24h verified by the Screening micturition diary~Exclusion Criteria:~* Post-void residual urine volume (PVR) of \> 200 ml as measured by an ultrasound~* Maximum urinary flow rate (Qmax) of \< 5 ml/second as measured by a flowmeter; a voided volume of 75 ml is required in order to accurately record the Qmax~* Prescribed and administered an antimuscarinic or antispasmodic within 1 month~* Prescribed and administered an a-1-adrenergic antagonist within 2 weeks

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunopharmacological Effects of Rituximab in Atopic Dermatitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must give written informed consent.~* Must be at least 18 years of age.~* Must have been diagnosed with atopic dermatitis fulfilling the diagnostic criteria of Hanfin and Rajka and having active inflammation.~* Must have a severity score of 6-9 according to Langeland and Rajka.~* Must have a PGA of severe or very severe and a pruritus score of moderate or severe at baseline.~Exclusion Criteria:~* Patients with other skin diseases that might interfere with the evaluation of AD.~* Patients with severe diseases of other organ systems (e.g. cardiovascular, liver, kidney, psychiatric, neurologic) that might put the patient on risk during the study or might interfere with the evaluations (in the opinion of the investigator).~* Patient older than 65 years.~* Systemic treatment for atopic dermatitis (e. g. corticosteroids, cyclosporine, mycophenolat-mofetil, interferon-gamma, UVB, UVA, PUVA) or systemic treatment with immunosuppressive/immunomodulating substances (e.g. azathioprin, methotrexate, biologics or hyposensitization -therapy) within 28 days prior to baseline.~* Local treatment for atopic dermatitis with pimecrolimus/tacrolimus, steroids \> class III, instable use of steroids class \<III, emollients or local antiseptics/antibiotics within 14 days prior to day 1.~* Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia) within 3 months prior to the first dose of Rituximab.~* History of recurrent clinically significant infection.~* Congenital or acquired immunodeficiency syndrome.~* History of or a new diagnosis or treatment of an invasive malignancy within 5 years of enrollment. Patients with a history of treated squamous cell and/or basal cell carcinomas limited to the skin are not excluded.~* For female patients, unless postmenopausal or surgically sterile, unwillingness to practice effective contraception, as defined by the investigator, during the study. The rhythm method is not to be used as the sole method of contraception. Female patients considering becoming pregnant while in the study are excluded.~* Female patients who are currently pregnant or breast-feeding.~* Current enrollment in any other investigational drug study.~* Previous participation in this study or previous studies with Rituximab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients with atopic dermatitis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Underwent curative hepatectomy;~* Diagnosis of HCC was confirmed by postoperative histopathology;~* Liver function Child-Pugh A or B;~* Performance status score 0 or 1~* With high risk factor of HCC recurrence, such as tumor size ≥ 5 cm, multinodular, macrovascular invasion or microvascular invasion; Receive immune checkpoint inhibitors based adjuvant therapy.~Exclusion Criteria:~* Receive neoadjuvant immune checkpoint inhibitors therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Immune checkpoint inhibitors based adjuvant therapy (Type: None): Patients in this arm will receive immune checkpoint inhibitors based adjuvant therapy.
- Without adjuvant therapy (Type: None): Patients in this arm will not receive any adjuvant therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult participants, \>/= 18 years of age~* Patients with rheumatoid arthritis for whom the rheumatologist decides to start tocilizumab in combination with DMARD or as monotherapy~Exclusion Criteria:~* Current participation in a clinical trial in rheumatoid arthritis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab (Type: None): Tocilizumab administered as monotherapy or in combination with other standard of care therapy according to prescribing information and normal clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis: Histologically confirmed Hodgkins lymphoma~* Relapsed or refractory disease after at least two prior lines of treatment~* Age 18-70 years old~* Signed informed consent~* No severe concurrent illness~Exclusion Criteria:~* Uncontrolled bacterial or fungal infection at the time of enrollment~* Requirement for vasopressor support at the time of enrollment~* Karnofsky index \<30%~* Pregnancy~* Somatic or psychiatric disorder making the patient unable to sign informed consent~* Active or prior documented autoimmune disease requiring systemic treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Nivolumab 40 mg (Type: EXPERIMENTAL): Experimental: Nivolumab Nivolumab 40 mg IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Locally advanced or metastatic breast cancer~* Measurable disease as per RECIST criteria~* No prior chemotherapy in the metastatic breast setting~* Prior chemotherapy and/or hormonal therapy for early stage breast cancer~* Adjuvant Herceptin is allowed~* Prior radiation therapy in either the metastatic or early stage setting~* Patients may have received any number of hormonal therapies~* Age \>18 years~* Only women are eligible for the study~* Able to perform activities of daily living with minimal assistance~* Normal organ and bone marrow function~* Patients who will be receiving Trastuzumab must have normal heart function~* Sign a written informed consent document~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Received prior chemotherapy for metastatic breast cancer~* Known leptomeningeal carcinomatosis~* Uncontrolled brain metastasis~* Uncontrolled intercurrent illness~* Pregnant or lactating~* History of other non-breast cancer malignancy~* Received prior chemotherapy for early stage breast cancer within 6 months~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with diagnosis of idiopathic Parkinson's Disease (PD) that is levodopa-responsive~* Participants must be judged by the investigator to be inadequately controlled by current therapy, have recognizable/identifiable Off and On states (motor fluctuations), and have a minimum of 2.5 hours of Off time per day~Exclusion Criteria:~* Participant is cognitively impaired and is not able to safely and effectively manage the drug delivery system and the diaries and is not able to adhere to the study~* Participant is considered by the investigator to be an unsuitable candidate to receive ABBV-951 for any reason

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABBV-951 Low Dose Subgroup (Type: EXPERIMENTAL): After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.
- ABBV-951 High Dose Subgroup (Type: EXPERIMENTAL): After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Propofol vs. Midazolam-based Balanced Propofol for Nonanesthesiologist Moderate Sedation in Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients undergoing elective outpatient colonoscopy~Exclusion Criteria:~* Age less than 18 years~* Allergy to propofol, soybeans, eggs or midazolam~* Chronic intake of benzodiazepines~* History of colorectal surgery~* ASA class IV, short and tick neck, difficult intubation due to inability to open the mouth widely~* Pregnancy~* Refusal, inability or unwillingness to give written consent~* Patients scheduled for advanced therapeutic colonoscopy or for more than one endoscopic procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Midazolam balanced propofol sedation (Type: ACTIVE_COMPARATOR): 2 mg midazolam in 2 ml saline midazolam followed by continuous propofol iv infusion
- Single-agent propofol sedation (Type: PLACEBO_COMPARATOR): 2 ml saline followed by continuous propofol iv infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Dexmedetomidine Sedation in Children for Non-painful Procedures

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children 2 months to 17 years (i.e. before their 18th birthday)~* Child will be receiving intranasal dexmedetomidine as part of their usual medical care~* Child will be undergoing a non-painful medical procedure, which includes (but is not limited to): MRI, CT scans, ABR/BAER, echocardiograms, and EEGs.~Exclusion Criteria:~* Known allergy to dexmedetomidine~* Known abnormal renal or hepatic function~* Known cardiac conduction abnormality or heart block~* Current use of digoxin or beta-blockers

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Intranasal dexmedetomidine (Type: None): Intranasal dexmedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete